


## Frovatriptan succinate hydrate

## Chemical Properties

CAS No.:	158930-17-7
Formula:	C <sub>18</sub> H <sub>25</sub> N <sub>3</sub> O <sub>6</sub>
Molecular Weight:	379.41
Appearance:	N/A
Storage:	0-4°C for short term (days to weeks), or -20°C for long term (months).



## Biological Description

Description	Frovatriptan succinate hydrate is effective in treating the full spectrum of migraine including the associated symptoms of nausea, vomiting, photophobia, and phonophobia. Frovatriptan succinate hydrate can also be used as in mini-prophylaxis in menstrual migraine. Frovatriptan succinate hydrate is a potent, high affinity, selective and orally active 5-HT <sub>1B</sub> , HT <sub>1D</sub> receptor agonist and a moderately potent 5-HT <sub>7</sub> receptor agonist, with pK <sub>i</sub> values of 8.6, 8.4, and 6.7, respectively.
Targets(IC <sub>50</sub> )	5-HT <sub>1B</sub> Receptor: 8.6 (pki) 5-HT <sub>1D</sub> Receptor: 8.4 (pki) Human 5-HT <sub>7</sub> Receptor: 6.7 (pki)
In vitro	Frovatriptan has a high affinity for 5-HT <sub>1B</sub> and 5-HT <sub>1D</sub> receptors and a moderate affinity for the 5-HT <sub>1A</sub> and 5-HT <sub>1F</sub> receptors subtypes. Frovatriptan has a moderate affinity for the 5-HT <sub>7</sub> receptors, an action associated with coronary artery relaxation in the dog. Cerebral vasodilatation and neurogenic inflammation are considered to be prime movers in the pathogenesis of migraine. Activation of 5-HT <sub>1B</sub> reverses cerebral vasodilatation and activation of 5-HT <sub>1D</sub> prevents neurogenic inflammation.
In vivo	Frovatriptan is chiefly metabolized by CYP1A2 and is cleared by the kidney and liver making moderate failure of either organ not a limiting factor in treatment. Frovatriptan has a low risk of interactions with other drugs. Oral bioavailability of Frovatriptan is 22%-30% and is not affected by food. Although the maximum concentration in the plasma is achieved in 2-3 hours, 60%-70% of this is achieved in 1 hour. A steady state is achieved in 4-5 days. Plasma protein binding is low at 15%. The most unique feature is the relative terminal long half-life of about 26 hours.

## Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.636 mL	13.178 mL	26.357 mL
5 mM	0.527 mL	2.636 mL	5.271 mL
10 mM	0.264 mL	1.318 mL	2.636 mL
50 mM	0.053 mL	0.264 mL	0.527 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

## Reference

1. Kelman L. Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat. 2008 Feb;4(1):49-54.
2. Comer MB. Et al. Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan. Headache. 2002 Apr;42 Suppl 2:S47-53.

[Inhibitors](#) · [Natural Compounds](#) · [Compound Libraries](#)

**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.**

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481